Harmeet Malhi1, Alina M Allen, Kymberly D Watt. 1. Division of Gastroenterology and Hepatology, William J. von Liebig Center for Transplantation and Clinical Regeneration, Mayo Clinic, Rochester, Minnesota, USA.
Abstract
PURPOSE OF REVIEW: Nonalcoholic steatohepatitis (NASH) is projected to become the most common indication for liver transplantation in the near future. NASH recipients have concurrent obesity, metabolic, and cardiovascular risks, which directly impact patient selection, posttransplant morbidity and potentially long-term outcomes. The purpose of this review is to highlight strategies to optimize pretransplant selection, outcomes, and posttransplant risk modification to optimize patient and graft survival. RECENT FINDINGS: NASH recipients are at risk for pretransplant cardiovascular disease, diabetes mellitus, and related renovascular complications. Stringent selection criteria identify those patients most likely to benefit from liver transplantation without adverse cardiovascular events yet, the incidence of these events remains high in NASH recipients. High BMI imparts postoperative morbidity because of infections, wound complications, and longer lengths of hospital stay. Aggressive management of modifiable risk factors such as obesity, hyperlipidemia, diabetes mellitus, and hypertension is recommended. SUMMARY: Although patient and graft survival in NASH recipients is excellent, long-term reduction in healthcare utilization and outcomes in these patients would benefit from risk factor modification. Periodic reassessment of coronary artery disease and early consideration of bariatric surgery is recommended in this population.
PURPOSE OF REVIEW: Nonalcoholic steatohepatitis (NASH) is projected to become the most common indication for liver transplantation in the near future. NASH recipients have concurrent obesity, metabolic, and cardiovascular risks, which directly impact patient selection, posttransplant morbidity and potentially long-term outcomes. The purpose of this review is to highlight strategies to optimize pretransplant selection, outcomes, and posttransplant risk modification to optimize patient and graft survival. RECENT FINDINGS: NASH recipients are at risk for pretransplant cardiovascular disease, diabetes mellitus, and related renovascular complications. Stringent selection criteria identify those patients most likely to benefit from liver transplantation without adverse cardiovascular events yet, the incidence of these events remains high in NASH recipients. High BMI imparts postoperative morbidity because of infections, wound complications, and longer lengths of hospital stay. Aggressive management of modifiable risk factors such as obesity, hyperlipidemia, diabetes mellitus, and hypertension is recommended. SUMMARY: Although patient and graft survival in NASH recipients is excellent, long-term reduction in healthcare utilization and outcomes in these patients would benefit from risk factor modification. Periodic reassessment of coronary artery disease and early consideration of bariatric surgery is recommended in this population.
Authors: Keith D Lindor; Kris V Kowdley; E Jenny Heathcote; M Edwyn Harrison; Roberta Jorgensen; Paul Angulo; James F Lymp; Lawrence Burgart; Patrick Colin Journal: Hepatology Date: 2004-03 Impact factor: 17.425
Authors: Ebenezer T Oni; Arthur S Agatston; Michael J Blaha; Jonathan Fialkow; Ricardo Cury; Andrei Sposito; Raimund Erbel; Ron Blankstein; Ted Feldman; Mouaz H Al-Mallah; Raul D Santos; Matthew J Budoff; Khurram Nasir Journal: Atherosclerosis Date: 2013-08-09 Impact factor: 5.162
Authors: L Fischer; J Klempnauer; S Beckebaum; H J Metselaar; P Neuhaus; P Schemmer; U Settmacher; N Heyne; P-A Clavien; F Muehlbacher; I Morard; H Wolters; W Vogel; T Becker; M Sterneck; F Lehner; C Klein; G Kazemier; A Pascher; J Schmidt; F Rauchfuss; A Schnitzbauer; S Nadalin; M Hack; S Ladenburger; H J Schlitt Journal: Am J Transplant Date: 2012-04-11 Impact factor: 8.086
Authors: Anas Safadi; Mohamed Homsi; Waddah Maskoun; Kathleen A Lane; Inder Singh; S G Sawada; Jo Mahenthiran Journal: Circulation Date: 2009-09-14 Impact factor: 29.690
Authors: André A S Dick; Austin L Spitzer; Catherine F Seifert; Alysun Deckert; Robert L Carithers; Jorge D Reyes; James D Perkins Journal: Liver Transpl Date: 2009-08 Impact factor: 5.799
Authors: J K Heimbach; K D S Watt; J J Poterucha; N Francisco Ziller; S D Cecco; M R Charlton; J E Hay; R H Wiesner; W Sanchez; C B Rosen; J M Swain Journal: Am J Transplant Date: 2012-11-08 Impact factor: 8.086
Authors: Mariya L Samoylova; Kara Wegermann; Brian I Shaw; Samuel J Kesseli; Sandra Au; Christine Park; Samantha E Halpern; Scott Sanoff; Andrew S Barbas; Yuval A Patel; Debra L Sudan; Carl Berg; Lisa M McElroy Journal: Liver Transpl Date: 2021-07-14 Impact factor: 6.112
Authors: Eva Montalvá; Manuel Rodríguez-Perálvarez; Annabel Blasi; Santiago Bonanad; Olga Gavín; Loreto Hierro; Laura Lladó; Elba Llop; Juan Carlos Pozo-Laderas; Jordi Colmenero Journal: Transplantation Date: 2022-01-04 Impact factor: 5.385
Authors: Giuseppina Pisano; Anna L Fracanzani; Lucio Caccamo; Maria F Donato; Silvia Fargion Journal: World J Gastroenterol Date: 2016-10-28 Impact factor: 5.742
Authors: Ivana Mikolasevic; Tajana Filipec-Kanizaj; Maja Mijic; Ivan Jakopcic; Sandra Milic; Irena Hrstic; Nikola Sobocan; Davor Stimac; Patrizia Burra Journal: World J Gastroenterol Date: 2018-04-14 Impact factor: 5.742
Authors: Harald Unterweger; Christina Janko; Marc Schwarz; László Dézsi; Rudolf Urbanics; Jasmin Matuszak; Erik Őrfi; Tamás Fülöp; Tobias Bäuerle; János Szebeni; Clément Journé; Aldo R Boccaccini; Christoph Alexiou; Stefan Lyer; Iwona Cicha Journal: Int J Nanomedicine Date: 2017-07-24
Authors: Mustafa Nazzal; Krista L Lentine; Abhijit S Naik; Rosemary Ouseph; Mark A Schnitzler; Zidong Zhang; Henry Randall; Vikas R Dharnidharka; Dorry L Segev; Bertram L Kasiske; Gregory P Hess; Tarek Alhamad; Mara McAdams-Demarco; David A Axelrod Journal: Transplant Direct Date: 2018-06-13